{"nctId":"NCT00430508","briefTitle":"Use of the Combination of Olmesartan and Hydrochlorothiazide in Essential Hypertension","startDateStruct":{"date":"2007-02"},"conditions":["Essential Hypertension"],"count":972,"armGroups":[{"label":"4","type":"EXPERIMENTAL","interventionNames":["Drug: olmesartan medoxomil (OM)/hydrochlorothiazide (HCTZ) tablets and placebo"]},{"label":"1","type":"EXPERIMENTAL","interventionNames":["Drug: olmesartan medoxomil/hydrochlorothiazide tablets"]},{"label":"3","type":"EXPERIMENTAL","interventionNames":["Drug: olmesartan medoxomil/hydrochlorothiazide tablets"]},{"label":"2","type":"EXPERIMENTAL","interventionNames":["Drug: olmesartan medoxomil (OM)/hydrochlorothiazide (HCTZ) tablets"]}],"interventions":[{"name":"olmesartan medoxomil (OM)/hydrochlorothiazide (HCTZ) tablets and placebo","otherNames":[]},{"name":"olmesartan medoxomil (OM)/hydrochlorothiazide (HCTZ) tablets","otherNames":[]},{"name":"olmesartan medoxomil/hydrochlorothiazide tablets","otherNames":[]},{"name":"olmesartan medoxomil/hydrochlorothiazide tablets","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Male or female Europeans aged 18 years or older with moderate to severe hypertension (HTN)\n\nExclusion Criteria:\n\n* Female patients of childbearing potential pregnant, lactating or planning to become pregnant during the trial period.\n* Patients with serious disorders which may limit the ability to evaluate the efficacy or safety of the study medication, including cerebrovascular, cardiovascular, renal, respiratory, hepatic, gastrointestinal, endocrine or metabolic, haematological or oncological, neurological and psychiatric diseases.\n* Patients having a history of the following within the last six months:\n\n  * myocardial infarction,\n  * unstable angina pectoris,\n  * percutaneous coronary intervention,\n  * severe heart failure,\n  * hypertensive encephalopathy,\n  * cerebrovascular accident (stroke) or\n  * transient ischaemic attack.\n* Patients with clinically significant abnormal laboratory values at screening.\n* Patients with secondary HTN.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change in Mean Trough Sitting Diastolic Blood Pressure From Week 8(Baseline) to Week 16","description":"Change = Week 16 - Week 8 (baseline).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-11.16","spread":"8.796"},{"groupId":"OG001","value":"-9.13","spread":"8.622"},{"groupId":"OG002","value":"-8.10","spread":"7.968"},{"groupId":"OG003","value":"-5.66","spread":"8.546"}]}]}]},{"type":"SECONDARY","title":"Change in Mean Trough Sitting Diastolic Blood Pressure From Week 8(Baseline) to Week 12.","description":"Change = Week 12 - Week 8 (baseline).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-8.74","spread":"7.879"},{"groupId":"OG001","value":"-7.72","spread":"7.606"},{"groupId":"OG002","value":"-6.66","spread":"7.090"},{"groupId":"OG003","value":"-4.47","spread":"7.197"}]}]}]},{"type":"SECONDARY","title":"Change in Mean Trough Sitting Systolic Blood Pressure From Week 8(Baseline) to Week 16.","description":"Change = Week 16 - Week 8 (baseline).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-16.17","spread":"13.444"},{"groupId":"OG001","value":"-13.52","spread":"14.533"},{"groupId":"OG002","value":"-11.46","spread":"13.673"},{"groupId":"OG003","value":"-8.85","spread":"13.537"}]}]}]},{"type":"SECONDARY","title":"Change in Mean Trough Sitting Systolic Blood Pressure From Week 8(Baseline) to Week 12.","description":"Change = Week 12 - Week 8 (baseline).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-13.16","spread":"13.337"},{"groupId":"OG001","value":"-10.90","spread":"12.297"},{"groupId":"OG002","value":"-9.65","spread":"11.743"},{"groupId":"OG003","value":"-6.60","spread":"10.932"}]}]}]},{"type":"SECONDARY","title":"Number of Patients Achieving Target Blood Pressure at Week 16","description":"Target Blood Pressure is diastolic blood pressure (dBP) \\< 90 mmHg and systolic blood pressure (sBP) \\< 140 mmHg for non-diabetics, and dBP \\< 80 mmHg and sBP \\< 130 mmHg for diabetics","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"59","spread":null},{"groupId":"OG001","value":"110","spread":null},{"groupId":"OG002","value":"88","spread":null},{"groupId":"OG003","value":"68","spread":null}]}]}]},{"type":"SECONDARY","title":"Change in Mean 24-hour Ambulatory Blood Pressure Monitoring Diastolic Blood Pressure From Week 8(Baseline) to Week 16.","description":"Change = Week 16 - Week 8 (baseline).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-7.2","spread":"7.62"},{"groupId":"OG001","value":"-5.3","spread":"8.60"},{"groupId":"OG002","value":"-4.1","spread":"9.07"},{"groupId":"OG003","value":"-2.0","spread":"7.64"}]}]}]},{"type":"SECONDARY","title":"Change in Mean Daytime Ambulatory Blood Pressure Monitoring Diastolic Blood Pressure From Week 8(Baseline) to Week 16.","description":"Change = Week 16 - Week 8 (baseline).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-7.0","spread":"8.06"},{"groupId":"OG001","value":"-5.5","spread":"9.10"},{"groupId":"OG002","value":"-4.0","spread":"9.34"},{"groupId":"OG003","value":"-1.8","spread":"8.39"}]}]}]},{"type":"SECONDARY","title":"Change in Mean Night-time Ambulatory Blood Pressure Monitoring Diastolic Blood Pressure From Week 8(Baseline) to Week 16.","description":"Change = Week 16 - Week 8 (baseline).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-7.9","spread":"9.51"},{"groupId":"OG001","value":"-4.5","spread":"9.90"},{"groupId":"OG002","value":"-4.2","spread":"10.61"},{"groupId":"OG003","value":"-2.3","spread":"8.47"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":null,"commonTop":[]}}}